Survivin、BCRP及HER-2基因在乳腺癌NE方案新辅助化疗前后表达的变化  

Expression changes of Survivin, BCRP and HER-2 genes after neoadjuvant chemotherapy of NE in breast cancer

作　　者：李迅[1] 欧江华[1] 朱丽萍[1] 杨顺娥[1] 章恒[1] 李妍[1] 

机构地区：[1]新疆医科大学附属肿瘤医院乳腺肿瘤诊疗中心,乌鲁木齐830011

出　　处：《中华实验外科杂志》2011年第12期2224-2226,共3页Chinese Journal of Experimental Surgery

基　　金：基金项目：新疆维吾尔自治区自然科学基金资助项目（2009211A06）

摘　　要：目的探讨Survivin、乳腺癌耐药蛋白（BCRP）及人类表皮生长因子受体（HER-2）基因预测乳腺癌NE方案新辅助化疗疗效的敏感性。方法对46例乳腺癌患者行NE方案新辅助化疗，应用逆转录-聚合酶链反应（RT-PCR）方法比较化疗前后Survivin、BCRP及HER-2表达差异并分析其与化疗疗效的关系。结果乳腺癌新辅助化疗NE方案总有效率为76．1％（35／46），其中临床完全缓解（cCR）占15．2％（7／46），病理完全缓解（pCR）占10．9％（5／46），部分缓解（cPR）为60．9％（28／46），稳定（SD）占21．7％（10／46），进展（PD）占2．2％（1／46）。化疗后SurvivinmRNA、BCRPmRNA及HER-2mRNA的阳性表达率均有下降，差异有统计学意义（P〈0．05）。SurvivinmRNA、BCRPmRNA及HER-2mRNA单独阴性表达的患者化疗近期有效率均较阳性表达者高（P〈0．05），三指标均为阴性表达组化疗疗效高于其他各组（P〈0．05），且各指标问无明显相关（P〉0．05）。结论联合检测Survivin、BCRP及HER-2的表达有助于预测乳腺癌NE方案新辅助化疗的敏感性。Objective To investigate Survivin, BCRP and HER-2 genes prediction and sensitivity of breast cancer in neoadjuvant chemotherapy with NE （ Vinorelbine and Epirubinein ）. Methods There were 46 cases of breast cancer patients with neoadjuvant chemotherapy NE program, using reverse transcription-polymerase chain reaction （RT-PCR） method to detect Survivin, BCRP and HER-2 expression before and after chemotherapy and to analyze the differences in the relationship with chemotherapy. Results Neoadjuvant chemotherapy NE overall response rate was 76. 1% （35/46）, which cCR accounted 15.2% （7/46）, pCR 10.9% （5/46）, cPR60.9% （28/46）, SD21.7% （10/46）, PD2.2% （1/46）, respectively. After chemotherapy, positive expression rates of Survivin mRNA, BCRP mRNA and HER-2 mRNA decreased, the difference was statistically significant （ P 〈 0. 05 ）. The efficient rate of the individual positive expression of Survivin mRNA, BCRP mRNA and HER-2 mRNA were lower than the negative groups （ P 〈 0. 05 ）, three indicators of negative expression with chemotherapy were lower than other groups （P 〈0. 05 ）. There was no relationship among the expression of Survivin mRNA, BCRP mRNA and HER-2 mRNA in breast cancer （ P 〉 0.05 ）. Conclusion The combined of detection the expression of Survivin, BCRP and HER-2 in NE program is helpful to predict sensitivity of neoadjuvant chemotherapy in breast cancer.

关 键 词：乳腺癌 新辅助化疗 SURVIVIN MRNA BCRP MRNA HER-2 MRNA 预测 NE方案 

分 类 号：R737.9[医药卫生—肿瘤]